At the current price of Regeneron, such an operation would be about $ 13 billion to Sanofi.
The giant French pharmaceutical Sanofi has announced this Monday to get rid of the bulk of its share in the biotech Regeneron, its american partner, valued at approximately $ 13 billion. “Sanofi announced today its intention to sell its stake in the capital of Regeneron”, which represents a little more than 20% of american society, said the French group in a press release, stating that their collaboration is ongoing and will continue normally.
READ ALSO >> “Scandal Sanofi” : when the reflexes pavloviens policies face the facts
Regeneron is the american partner of Sanofi, with which it has developed multiple treatments in recent years. Their alliance also has a presence of French in the capital of the us. It must now come to an end, at least for the most part. Of the 23.2 million shares that it holds, Sanofi expects to retain only 400 000. At the current price of Regeneron, such an operation would be about $ 13 billion to Sanofi.
Your support is essential. Subscribe for $ 1 support Us
About 8 billion shares available on the market
of this amount, 5 billion is reserved for Regeneron, will conduct a repurchase of its own shares. The rest will be put back on the market. Sanofi will soon file papers with the SEC, the gendarme of the us markets. “The collaboration between Sanofi and Regeneron has been one of the most productive in the pharmaceutical sector”, stated in the press release Paul Hudson, chief executive officer of Sanofi.
READ ALSO >> Nicolas Bouzou : “The French feel of this case Sanofi as a humiliation,”
“It has allowed us to create value for our two companies, and, especially, to develop five drugs of major importance to patients,” he continued. The two companies have developed jointly the Dupixent has already been launched in over thirty countries for several pathologies, including asthma and eczema. “Sanofi is committed to continuing its collaboration with Regeneron, which still fits fully into our overall strategy,” noted Paul Hudson.
Read our complete file
Sanofi
André Loesekrug-Pietri : “The CEO of Sanofi is right on the lack of european response” Vaccine against the Covid-19 : what is known of the controversy over the Sanofi group action against Sanofi : health Insurance is moved to the side of 115 million euros
Even if Sanofi, who had referred to the end of 2019 the possibility of selling its stake in Regeneron, does not detail the capital gain potential, it promises to be considerable. This very secondarily since 2004 in the capital of the u.s., the French waited for 2007 to take the bulk of its stake, at a time when the share price of Regeneron was 20 times less than today.